CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 128 enrolled
Drug / intervention
Facial Moisturizer with SPF 50+drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01892657
NCT01892657Phase 4Completed

Cetaphil® Daily Facial Moisturizer With Sunscreen SPF 50+ - Human Repeat Insult Patch Test Skin Irritation/Sensitization Evaluation (Semi-occlusive Patch)

Galderma R&D·interventional·Posted Jul 4, 2013·Updated Aug 1, 2022

In Brief

A Phase 4 clinical trial evaluating Facial Moisturizer with SPF 50+ for Skin Irritation. Completed, enrolled 128 participants across 1 site.

Detailed Summary

This study examined the possible sensitization and irritation effects of a moisturizer with sunscreen SPF 50+.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSkin Irritation
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 4, 2013
Enrollment StartMar 1, 2008
Primary CompletionMay 1, 2008
Study CompletionAug 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 13.0 years ago

Interventions

Facial Moisturizer with SPF 50+drug

All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+